Circulating Tumor Cells (CTC) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Circulating Tumor Cells (CTC) Market is segmented by Technology (CTC Enrichment Methods and CTC Detection Methods), Application, and Geography.

Circulating Tumor Cells (CTC) Market Snapshot

Circulating Tumor Cells (CTC) Market
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Europe
Largest Market: North America
CAGR: 9.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The circulating tumor cells (CTC) market is expected to register a CAGR of 9.5% during the forecast period. The major factors for the growth of the circulating tumor cells (CTC) market include the advancements in biomedical imaging and bioengineering technology, rising demand for preventive medicine and companion diagnostics, and growing prevalence of cancer.

The global cancer burden is increasing, and thus, cancer therapies must be modified according to regional and national priorities. According to the World Cancer Research Fund, in 2018, there were 18 million cancer cases around the world, out of which, 9.5 million cases were in men and 8.5 million in women. Lung and breast cancers were the most common and contributed about 12.3% of the total number of new cases that were diagnosed in 2018. Almost half of the cancer prevalence occurs in Asia, and in Europe, one-quarter of the population is suffering from cancer. In the Americas, 21% of the population is suffering from cancer. The increasing cancer burden is due to a number of factors, including population growth and aging and the changing prevalence of certain causes of cancer linked to social and economic development.

According to the Globocan Database, in 2018, it was estimated that the number of new cases would grow from 18.1 million to 29.4 million, between 2018 and 2040. Thus, the increasing prevalence of cancer is one of the major factors that are augmenting the growth of the market.

Scope of the Report

As per the scope of this report, circulating tumor cells (CTC) refer to the tumor cells that circulate inside the body through the blood circulatory system and lymphatic system. Factors, such as the high prevalence of cancer, advancements in biomedical imaging and bioengineering technology, and increased demand for preventive medicine, along with the need for companion diagnostics, drive the circulating tumor cells market, globally. The circulating tumor cells (CTC) market is segmented by technology, application, and geography.

By Technology
CTC Enrichment Methods
Positive Enrichment
Negative Enrichment
Other Technologies
CTC Detection Methods
Immunocytochemical Technology
Molecular (RNA)-based Technology
Other CTC Detection Methods
By Application
Multiple Chromosome Abnormalities
RNA Profiling
Protein Expression
Cellular Communication
Other Applications
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East & Africa
GCC
South Africa
Rest of Middle-East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Negative Enrichment Segment is is Expected to Hold a Major Market Share in the Circulating Tumor Cells (CTC) Market

In the case of the positive enrichment method, it cannot isolate CTCs depending on heterogeneous properties, but negative enrichment method can isolate heterogeneous and intact CTCs by specifically eliminating blood cells. The rising prevalence of the various types of cancer is expected to drive the overall growth of the market. 

According to the WHO, in 2018, approximately 70% of the deaths in low- and middle-income countries were due to cancer. With this growing burden, prevention of cancer is one of the most significant challenges. The analysis of circulating tumor cells is a significant aspect for monitoring disease progression or response to treatment, specifically as a companion diagnostic for new anticancer drugs, and for research into the mechanisms of disease progression. 

In addition, negative enrichment has advantages over positive enrichment in isolating CTCs, owing to which the segment is expected to witness high growth over the forecast period.

Circulating Tumor Cells (CTC) Market

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

In 2018, as per the American Cancer Society, more than 15.5% of Americans had a history of cancer, of which a majority had been diagnosed in the past two years. A number of new cases are being reported, with about 1.7 million new cases being reported in 2018. Based on healthcare expenditure, the United States is among the major countries across the world, which spends about 17.1% of its total GDP on healthcare. The expenditure for cancer patients is more in breast, lung, and colon and rectum cancers. 

The United States has one of the highly successful products, CellSearch Circulating Tumor Cell Kit, which was approved by the US Food and Drug Administration (FDA). The product has reimbursement facility through various public and private payers in several states of the country, such as Cigna Government Services, Noridian, and United HealthCare, among others. Several universities across the United States, have relied on CTCs applications to advance the practice of pathology and laboratory medicine. Thus, owing to the all aforementioned factors, the market studied is expected to witness high growth over the forecast period.

Circulating Tumor Cells (CTC) Market

Competitive Landscape

The market studied is a moderately consolidated market, owing to the presence of small and large market players. Some of the market players are Advanced Cell Diagnostics Inc., Aviva Biosciences, Biocept Inc., Creatv Micro Tech, Inc., LungLife AI Inc., Menarini Silicon Biosystems, Miltenyi Biotec, Precision For Medicine (Formerly ApoCell), and Qiagen NV.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Advancements in Biomedical Imaging and Bioengineering Technology

      2. 4.2.2 Rising Demand for Preventive Medicine and Companion Diagnostics

      3. 4.2.3 Increasing Prevalence of Cancer

    3. 4.3 Market Restraints

      1. 4.3.1 Technical Difficulties in Detection and Characterization of CTCs Associated with High Cost of Diagnosis

      2. 4.3.2 Lack of Awarness and Unwillingness for the Adoption of Advanced CTC Technologies

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Technology

      1. 5.1.1 CTC Enrichment Methods

        1. 5.1.1.1 Positive Enrichment

        2. 5.1.1.2 Negative Enrichment

        3. 5.1.1.3 Other Technologies

      2. 5.1.2 CTC Detection Methods

        1. 5.1.2.1 Immunocytochemical Technology

        2. 5.1.2.2 Molecular (RNA)-based Technology

        3. 5.1.2.3 Other CTC Detection Methods

    2. 5.2 By Application

      1. 5.2.1 Multiple Chromosome Abnormalities

      2. 5.2.2 RNA Profiling

      3. 5.2.3 Protein Expression

      4. 5.2.4 Cellular Communication

      5. 5.2.5 Other Applications

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East & Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East & Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Advanced Cell Diagnostics Inc.

      2. 6.1.2 Aviva Biosciences

      3. 6.1.3 Biocept Inc.

      4. 6.1.4 Creatv Micro Tech Inc.

      5. 6.1.5 LungLife AI Inc.

      6. 6.1.6 Menarini Silicon Biosystems

      7. 6.1.7 Miltenyi Biotec

      8. 6.1.8 Precision for Medicine (Formerly ApoCell)

      9. 6.1.9 Qiagen NV

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Circulating Tumor Cells (CTC) Market market is studied from 2018 - 2026.

The Circulating Tumor Cells (CTC) Market is growing at a CAGR of 9.5% over the next 5 years.

Europe is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Menarini Silicon Biosystems, Miltenyi Biotec, Precision For Medicine (Formerly ApoCell), Qiagen NV, Biocept Inc are the major companies operating in Circulating Tumor Cells (CTC) Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!